Terms: = Ovarian cancer AND uPA AND Clinical Outcome
3 results:
1. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract] [Full Text] [Related]
2. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
3. clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
[TBL] [Abstract] [Full Text] [Related]